PMID- 28194716 OWN - NLM STAT- MEDLINE DCOM- 20170309 LR - 20181113 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 34 IP - 3 DP - 2017 Mar TI - Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-alpha. PG - 44 LID - 10.1007/s12032-016-0864-3 [doi] AB - Dendritic cells (DCs)-based tumor vaccines have shown to be the promising methods for inducing therapeutic antitumor response. However, DCs alone rarely carry curative antitumor activity, and the immunosuppressive microenvironment may contribute to this defect of DC vaccinal function. Irradiation in combination with DCs has been shown to promote immune-mediated tumor destruction in preclinical studies. However, little is known about how irradiation alters the tumor microenvironment, and what host pathways modulate the activity of administrated DCs. In this study, BALB/c mice and the 4T1 breast cancer cell line were used in a tumor-bearing model. The tumor-bearing mice were irradiated locally up to 10 Gy for 3 consecutive days or a single dose of 30 Gy using a cesium source. Studies of dynamic change of the tumor microenvironment in irradiated versus untreated tumors revealed that there was no obvious change on IL-10, IL-6 and TGF-beta expression or production, whereas increased TNF-alpha level within the first 2 weeks of irradiation. The increased TNF-alpha level is exactly right timing window for DCs injection, corresponding to the significant elevation of intratumoral CD8(+) T infiltration and the regression of tumor size. With attention to scheduling, combination X-ray with DCs i.t. injection may offer a practical strategy to improve treatment outcomes. FAU - Chang, Lijia AU - Chang L AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. FAU - Zhang, Zhengzheng AU - Zhang Z AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. FAU - Chen, Fang AU - Chen F AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. FAU - Zhang, Wen AU - Zhang W AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. FAU - Song, Shuang AU - Song S AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. FAU - Song, Shuxia AU - Song S AD - Department of Immunology and Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050017, People's Republic of China. songsxmy@hebmu.edu.cn. LA - eng PT - Journal Article DEP - 20170213 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Animals MH - Antigen Presentation MH - Cell Line, Tumor MH - Dendritic Cells/*immunology/*radiation effects MH - Female MH - Immunotherapy, Adoptive/*methods MH - Lymphocytes, Tumor-Infiltrating/immunology/radiation effects MH - Mammary Neoplasms, Experimental/*immunology/*therapy MH - Mice MH - Mice, Inbred BALB C MH - Mice, Inbred C57BL MH - Random Allocation MH - T-Lymphocytes, Cytotoxic/immunology/radiation effects MH - Tumor Microenvironment/immunology/radiation effects MH - Tumor Necrosis Factor-alpha/*biosynthesis/immunology OTO - NOTNLM OT - DC vaccine OT - Irradiation OT - Microenvironment OT - TNF-alpha OT - Tumor-bearing mice EDAT- 2017/02/15 06:00 MHDA- 2017/03/10 06:00 CRDT- 2017/02/15 06:00 PHST- 2016/07/17 00:00 [received] PHST- 2016/11/30 00:00 [accepted] PHST- 2017/02/15 06:00 [entrez] PHST- 2017/02/15 06:00 [pubmed] PHST- 2017/03/10 06:00 [medline] AID - 10.1007/s12032-016-0864-3 [pii] AID - 10.1007/s12032-016-0864-3 [doi] PST - ppublish SO - Med Oncol. 2017 Mar;34(3):44. doi: 10.1007/s12032-016-0864-3. Epub 2017 Feb 13.